ReviewFibrosis

Tissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies

See allHide authors and affiliations

Science Translational Medicine  31 Jan 2018:
Vol. 10, Issue 426, eaan5174
DOI: 10.1126/scitranslmed.aan5174

Article Information

vol. 10 no. 426

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 25, 2017
  • Accepted for publication January 8, 2018
  • .

Author Information

  1. Dario R. Lemos1,2,*, and
  2. Jeremy S. Duffield3,4,*,
  1. 1Renal Division, Brigham and Women’s Hospital, Boston, MA 02115, USA.
  2. 2Harvard Medical School, Boston, MA 02115, USA.
  3. 3Department of Medicine, University of Washington, Seattle, WA 98195, USA.
  4. 4Research and Development, Vertex Pharmaceuticals, Boston, MA 02210, USA.
  1. *Corresponding author. Email: dlemos{at}bwh.harvard.edu (D.R.L.); jeremysd{at}u.washington.edu (J.S.D.)
    • These authors contributed equally to this work.

    Altmetric

    Article usage

    Article usage: January 2018 to September 2020

    AbstractFullPdf
    Jan 2018100485148
    Feb 20183326251464
    Mar 201824384108
    Apr 20182475960
    May 20184197571
    Jun 20183824958
    Jul 20181663445
    Aug 20181937945
    Sep 20181434526
    Oct 20181414931
    Nov 20181857252
    Dec 20181443525
    Jan 2019984530
    Feb 20193414780
    Mar 20192014080
    Apr 20193513559
    May 201922124109
    Jun 20192415275
    Jul 20191913967
    Aug 2019178258
    Sep 20192610954
    Oct 20192811170
    Nov 2019219923
    Dec 20193011170
    Jan 20201810461
    Feb 20201510442
    Mar 2020247268
    Apr 2020237251
    May 2020107460
    Jun 2020156137
    Jul 202065716
    Aug 202095629
    Sep 2020197650

    Stay Connected to Science Translational Medicine

    Navigate This Article